Leflunomide

CAS 75706-12-6 8 current records 1 historicalSmall Molecule

Who holds supplier records for Leflunomide? 8 organisations hold a current record for Leflunomide: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 6 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (5), Taiwan (1), Argentina (1) and Germany (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Leflunomide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/leflunomide

Reading the evidence

  • 8 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    5 of the 8 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 6 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (8)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Leflunomide. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Leflunomide sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (6)

Certificates of Suitability on the EDQM register for Leflunomide, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

HolderCountryCertificateIssuedEU GMP at holder's address
BO-CHEM PRIVATE LIMITED MumbaiIN
CEP 2025-062 - Rev 00
Leflunomide
Apr 2026—
EMCURE PHARMACEUTICALS LIMITED PuneIN
CEP 2018-269 - Rev 03
Leflunomide
Mar 2026—
MAPRIMED S.A. Buenos AiresAR
CEP 2018-252 - Rev 03
Leflunomide
Dec 2025Inspected Jul 2025
France
FORMOSA LABORATORIES, INC. TaoyuanTW
CEP 2009-035 - Rev 03
Leflunomide
Jul 2025Inspected May 2025
Poland
ALEMBIC PHARMACEUTICALS LIMITED VadodaraIN
CEP 2007-172 - Rev 03
Leflunomide, Micronised
Jun 2025—
CIPLA LIMITED MumbaiIN
R1-CEP 2007-050 - Rev 01
Leflunomide
Jul 2014—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (1)

Organisations whose Type II DMFs for Leflunomide are no longer active. These show a past filing, not current supply.

Show all 1 historical record

Overview

Leflunomide is an immunomodulatory drug primarily used for the treatment of active moderate to severe rheumatoid arthritis. It works by inhibiting dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis, thus reducing lymphocyte proliferation.

Chemical identity

IUPAC name
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
Canonical SMILES
CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F
InChIKey
VHOGYURTWQBHIL-UHFFFAOYSA-N
Synonyms
Arava API, arava, hwa-486, l04aa13, leflunomide medac, leflunomide ratiopharm, leflunomide teva, leflunomide winthrop, nsc-677411, nsc-759864, repso, su-101

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Antirheumatic Agent

Therapeutic areas

RheumatologyImmunology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Leflunomide?

8 organisations hold an active US FDA Type II Drug Master File or a CEP for Leflunomide: Alembic Pharmaceuticals Limited (India), Cipla Limited (India), Emcure Pharmaceuticals Limited (India), Formosa Laboratories, Inc. (Taiwan), MAPRIMED SA (Argentina), EUROAPI GERMANY GMBH (Germany), RAKSHIT DRUGS PVT LTD (India) and BO-CHEM PRIVATE LIMITED (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Leflunomide Drug Master Files are active?

Alembic Pharmaceuticals Limited (DMF 16112), Cipla Limited (DMF 16109), Emcure Pharmaceuticals Limited (DMF 16124), Formosa Laboratories, Inc. (DMF 16038), MAPRIMED SA (DMF 32988), EUROAPI GERMANY GMBH (DMF 8116) and RAKSHIT DRUGS PVT LTD (DMF 43580). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Leflunomide records mean?

1 organisation has only inactive Type II DMFs for Leflunomide. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Leflunomide have a European Certificate of Suitability?

Yes. 6 organisations hold a valid CEP for Leflunomide on the EDQM register, including BO-CHEM PRIVATE LIMITED Mumbai (IN), EMCURE PHARMACEUTICALS LIMITED Pune (IN), MAPRIMED S.A. Buenos Aires (AR), FORMOSA LABORATORIES, INC. Taoyuan (TW), ALEMBIC PHARMACEUTICALS LIMITED Vadodara (IN) and CIPLA LIMITED Mumbai (IN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Leflunomide supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Leflunomide?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.